PNC Financial Services Group Inc. Acquires 6,268 Shares of Hinge Health Inc. $HNGE

PNC Financial Services Group Inc. lifted its stake in Hinge Health Inc. (NYSE:HNGE) by 172.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,898 shares of the company’s stock after acquiring an additional 6,268 shares during the period. PNC Financial Services Group Inc.’s holdings in Hinge Health were worth $382,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets increased its holdings in shares of Hinge Health by 162.7% during the 4th quarter. BNP Paribas Financial Markets now owns 727,672 shares of the company’s stock worth $33,800,000 after purchasing an additional 450,643 shares during the period. UBS Group AG lifted its stake in shares of Hinge Health by 168.8% in the fourth quarter. UBS Group AG now owns 356,701 shares of the company’s stock valued at $16,569,000 after buying an additional 223,980 shares during the period. Royce & Associates LP acquired a new stake in Hinge Health during the fourth quarter worth about $2,091,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Hinge Health by 755.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company’s stock valued at $1,271,000 after acquiring an additional 24,155 shares during the period. Finally, Alkeon Capital Management LLC raised its holdings in Hinge Health by 110.4% in the 4th quarter. Alkeon Capital Management LLC now owns 791,104 shares of the company’s stock valued at $36,747,000 after acquiring an additional 415,093 shares in the last quarter.

Insider Activity

In other news, major shareholder Insight Holdings Group, Llc sold 181,499 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $90.20, for a total value of $16,371,209.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $85.05, for a total transaction of $7,087,556.70. Following the sale, the chairman owned 83,334 shares of the company’s stock, valued at $7,087,556.70. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 3,721,100 shares of company stock worth $288,210,699. Corporate insiders own 18.92% of the company’s stock.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Strong Q2 performance: Hinge Health reported $212.8 million in second-quarter revenue, up 53% year over year. Earnings of $0.59 per share exceeded the $0.28 analyst consensus cited by MarketBeat, while management highlighted stronger member conversion, improved margins and free cash flow that more than tripled from the prior year. Hinge Health quarterly earnings report
• Positive Sentiment: Raised outlook: The company forecast third-quarter revenue of $223 million to $225 million, above the roughly $211 million consensus estimate, and projected 2026 revenue of $856 million to $860 million. The guidance suggests continued momentum in its digital musculoskeletal and migraine-care businesses. Hinge Health 2026 revenue forecast
• Positive Sentiment: Analyst price-target increases: Needham raised its target to $97 from $76 and maintained a Buy rating. Wells Fargo raised its target to $103 from $90 with an Overweight rating, while Citizens JMP lifted its target to $107 from $96 and maintained Market Outperform. The revisions indicate increased confidence in HNGE’s growth prospects.
• Positive Sentiment: Expansion into gastrointestinal care: Hinge Health agreed to acquire Cylinder Health for $105 million in cash. The deal is intended to add a virtual-first gastrointestinal-care program to its existing offerings; management said GI conditions affect about one in four U.S. adults and represent a large healthcare spending opportunity. Broader rollout is planned for 2027. Hinge Health Cylinder Health acquisition
• Neutral Sentiment: Key risks remain: Hinge Health continues to report a negative net margin and negative return on equity, while the cash acquisition introduces integration and execution risks. Its elevated valuation also leaves the stock sensitive to any slowdown in growth or weaker-than-expected adoption of new care programs.

Hinge Health Price Performance

Hinge Health stock opened at $80.00 on Thursday. The company has a market capitalization of $6.19 billion, a PE ratio of 62.50 and a beta of 1.30. Hinge Health Inc. has a one year low of $30.08 and a one year high of $91.50. The business has a 50 day simple moving average of $75.05 and a 200 day simple moving average of $54.43.

Hinge Health (NYSE:HNGE) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.28 by $0.31. Hinge Health had a return on equity of 65.44% and a net margin of 15.15%.The business had revenue of $212.82 million for the quarter. During the same period in the prior year, the firm earned $0.59 EPS. Hinge Health’s quarterly revenue was up 53.0% compared to the same quarter last year. Equities analysts anticipate that Hinge Health Inc. will post 1.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on HNGE. Citigroup reissued an “outperform” rating on shares of Hinge Health in a report on Monday, July 27th. Truist Financial raised their target price on Hinge Health from $79.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Wall Street Zen downgraded shares of Hinge Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Barclays increased their price objective on shares of Hinge Health from $97.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Canaccord Genuity Group set a $105.00 price objective on shares of Hinge Health in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Hinge Health currently has an average rating of “Moderate Buy” and an average price target of $98.64.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.